Key clinical point: Dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
Major finding: Dapagliflozin cut the incidence of substantially worsened chronic kidney disease by an average of 39% compared with placebo when added to standard treatment, with a number needed to treat of 19 to prevent one primary outcome event.
Study details: DAPA-CKD randomized 4,304 patients with chronic kidney disease to receive dapagliflozin or placebo over a mean of 24 years.
Disclosures: Dr. Heerspink has been a consultant to and received research funding from AstraZeneca and from several other companies.
FROM ESC CONGRESS 2020